Digest Network Come funziona
Network
/
Società
F.
Non verificato

F. Hoffmann-La Roche Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaPubblicità/Marketing/Media/Comunicazione

123 comunicati stampa

Guarda tutti i comunicati
23/03/2026
Farmaceutica
Annunci Economici
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
16/03/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
10/03/2026
Farmaceutica
Annunci Economici
Assemblée générale annuelle 2026 de Roche
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
10/03/2026
Farmaceutica
Annunci Economici
Roche Annual General Meeting 2026
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/03/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
06/03/2026
Farmaceutica
Annunci Economici
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/03/2026
Farmaceutica
Annunci Economici
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
01/03/2026
Farmaceutica
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
19/02/2026
Farmaceutica
Annunci Economici
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0
16/02/2026
Farmaceutica
Annunci Economici
Change to the Roche Enlarged Corporate Executive Committee
Fonte
F. Hoffmann-La Roche Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0